ADC Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in two upcoming investor conferences. The company's CEO Ameet Mallik will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET, and at the Jefferies Global Healthcare Conference on June 5, 2025, from 9:55-10:25 a.m. ET. Both presentations will be in a fireside chat format and available via webcast on the company's investor relations website, with replays accessible for approximately 30 days after each event.

LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences:

RBC Capital Markets Global Healthcare Conference
Date: May 21, 2025
Presentation Time: 10:30-10:55 a.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
To register for the webcast, click here.

Jefferies Global Healthcare Conference
Date: June 5, 2025
Presentation Time: 9:55-10:25 a.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
To register for the webcast, click here.

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML, the timing of the PFS events for LOTIS-5 and the results of the trial, the expected cash runway into the second half of 2026 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the Company's ability to grow ZYNLONTA^® revenue in the United States; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-present-at-upcoming-investor-conferences-302456009.html

SOURCE ADC Therapeutics SA

FAQ

When is ADC Therapeutics (ADCT) presenting at the RBC Capital Markets Healthcare Conference in 2025?

ADC Therapeutics will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET.

Who will be presenting at the Jefferies Global Healthcare Conference for ADC Therapeutics?

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, will be presenting at the Jefferies Global Healthcare Conference.

How long will the webcasts be available for viewing on ADC Therapeutics' website?

The webcasts will be available for replay for approximately 30 days following each event on ADC Therapeutics' investor relations website.

What format will the ADC Therapeutics presentations be in at both healthcare conferences?

Both presentations will be in a fireside chat format at the RBC Capital Markets and Jefferies healthcare conferences.